Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
-
Published:2024-06
Issue:6
Volume:9
Page:103466
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Marmé F.ORCID,
Martin M.,
Untch M.ORCID,
Thode C.ORCID,
Bonnefoi H.,
Kim S.-B.,
Bear H.ORCID,
Mc Carthy N.,
Gelmon K.ORCID,
García-Sáenz J.A.ORCID,
Kelly C.M.,
Reimer T.ORCID,
Valota O.,
Toi M.ORCID,
Rugo H.S.,
Gnant M.ORCID,
Makris A.,
Bassy M.,
Zhang Z.,
Furlanetto J.,
Nekljudova V.ORCID,
Loibl S.
Funder
Gilead Sciences
Novartis
Pfizer Inc